HighTower Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

HighTower Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-119,741	Closed	-$402K	–	4085
2023 Q4	$402K	Hold	119,741	–	–	﹤0.01%	2480
2023 Q3	$285K	Hold	119,741	–	–	﹤0.01%	2639
2023 Q2	$211K	Hold	119,741	–	–	﹤0.01%	2826
2023 Q1	$370K	Buy	119,741 +3,700	+3%	+$22.2K	﹤0.01%	2306
2022 Q4	$615K	Hold	116,041	–	–	﹤0.01%	1983
2022 Q3	$409K	Buy	116,041 +82,041	+241%	+$271K	﹤0.01%	2153
2022 Q2	$88K	Buy	+34,000	New	+$94.5K	﹤0.01%	2815

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

HighTower Advisors's PSTX Position: Q1 2024 in Review

HighTower Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2024, closing a stake of 119,741 shares — an estimated $402K sold.

HighTower Advisors first reported a position in PSTX in Q2 2022 and held it in 7 quarters. The position peaked at $615K in Q4 2022. 91 funds tracked by Wall St. Rank hold PSTX as of Q1 2024.

HighTower Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
HighTower Advisors sold 119,741 Poseida Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $402K.
HighTower Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
HighTower Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $615K in Q4 2022.
91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2024.

Based on HighTower Advisors's 13F filing for Q1 2024, filed 6 May 2024.